Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

Inclusion Criteria: Biopsy of breast mass was performed under ultrasound-guided treatment before neoadjuvant chemotherapy, and the diagnosis of breast cancer was confirmed pathologically, followed by immunohistochemical examination. Pathological sections before and after neoadjuvant chemotherapy were jointly diagnosed by 3 or more senior pathologists, and there were consistent definite conclusions. Have detailed and complete clinicopathological data; Diagnosis data of TCM syndrome type; No biopsy-confirmed lymph node metastasis; No serious systemic disease, able to tolerate neoadjuvant chemotherapy and surgical treatment; At least 4 cycles of neoadjuvant chemotherapy were completed, and the efficacy of chemotherapy was evaluated at the end of chemotherapy and after surgery; Under the guidance of doctors, take Xihuang pills in a standardized way throughout the whole process and review regularly; The patient did not receive any antitumor therapy drugs associated with the tumor prior to neoadjuvant chemotherapy; All patients were newly diagnosed Exclusion Criteria: Concurrent malignant tumors of other sites; Patients with distant metastasis Male breast cancer Patients who did not receive full-course standardized neoadjuvant chemotherapy; Lost contact or dropped out of the study, unable to follow up; Inability to tolerate chemotherapy responses; Intolerant to Xihuang Wan and unable to take it; The patient has strong side effects of chemotherapy and cannot tolerate chemotherapy drugs; Inflammatory breast cancer, bilateral breast cancer, paget's disease and other special types of breast cancer; Various other possible influences.